As pioneers in clinical trials, Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis, a fatal disease that can lead to heart failure suffered by some 200,000 - 250,000 people worldwide.

The single-dose treatment known as NTLA- 2001, based on the Nobel Prize-winning CRISPR-Cas9 genetic technology, has been developed by US company Intellia Therapeutics. Richmond is proud to have dosed the first person in the world with this new genetic therapy in Intellia’s Phase 1 study of healthy volunteers which we carried out in 2021. Now, thanks to the promising results of that study, Intellia has commissioned trials on a much larger group of patients, a Phase 3 study they are calling MAGNITUDE.

Richmond’s CEO Dr Jorg Taubel said: “Our mission has always been to accelerate therapies to market, bridging the gap between hope and answers for patients so we are delighted that our pioneering approach is advancing the prospect of a cure for ATTR Amyloidosis.”

Intellia Therapeutics announced the MAGNITUDE study on Monday 18th March 2024. Read their full announcement here.

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event